Abstract 478P
Background
Lung cancer is commonly diagnosed after 40 years old and surgical lung resection is the recommended treatment for early stage lung cancer. The mean age of presentation is around 70 years old but there remained concerns on performing surgery in these patients. These concerns were addressed with advances in surgical technique and we aimed to review our experience of performing curative lung resection in patients above 70 years old.
Methods
We performed a retrospective review of all patients who underwent curative surgery for primary lung cancers between 2018 and 2021 and compared the outcome between patients 70 years old and above against those who were younger.
Results
289 were reviewed, of which 180 patients (62.3%) were under 70 years old and 109 patients (37.7%) were 70 years old and above. Patients above 70 years had a significantly higher incidence of hypertension, hyperlipidemia, diabetes mellitus, ischaemic heart disease and renal impairment but there was no significant difference in the incidence of previous stroke, atrial fibrillation, congestive heart failure and chronic obstructive pulmonary disease. There was also no significant difference between the pre-operative FEV1 and DLCO between the 2 groups of patients. Patients above 70 years old were at higher risk of developing pneumonia (OR 2.28, 95% CI 1.65-3.13, p = 0.003), respiratory failure (OR 2.71, 95% CI 2.33-3.16, p = 0.020) and unplanned return to the ICU (OR 2.41, 95% CI 1.78-3.27, p = 0.005). Peri-operative mortality was also higher in patients above 70 years old but this was statistically not significant. (OR 1.94, CI 1.18-3.17, p = 0.073). There was no significant difference in the post-operative incidence of cardiac, renal or wound complications. No patients developed a peri-operative stroke.
Conclusions
Our study demonstrated that patients above 70 years old may be more susceptible to pulmonary complications such as pneumonia and respiratory failure that may in turn lead to higher peri-operative mortality. Care can be taken to mitigate these complications such as pre-operative pulmonary rehabilitation and early mobilisation but this should not preclude patients above 70 years old from undergoing curative lung resection surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract